Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies
Year: 2022
Type: article
Abstract: Objective: In this study, we determined whether Helicobacter pylori (H. pylori) infection dampens the efficacy of cancer immunotherapies. Design: Using mouse models, we evaluated whether immune checkpoint inhibitors or vaccine-based immunotherapies are effective in reducing tumour volumes of H. pylori-infected mice. In humans, we evaluated the correlation between H. pylori seropositivity and the efficacy of the programmed cell death protein 1 (PD-1) blockade therapy in patients with non-small-cell lung cancer (NSCLC). Results: In mice engrafted with MC38 colon adenocarcinoma or B16-OVA melanoma cells, the tumour volumes of non-infected mice undergoing anticytotoxic T-lymphocyte-associated protein 4 and/or programmed death ligand 1 or anti-cancer vaccine treatments were significantly smaller than those of infected mice. We observed a decreased number and activation status of tumour-specific CD8+ T cells in the tumours of infected mice treated with cancer immunotherapies independent of the gut microbiome composition. Additionally, by performing an in vitro co-culture assay, we observed that dendritic cells of infected mice promote lower tumour-specific CD8+ T cell proliferation. We performed retrospective human clinical studies in two independent cohorts. In the Dijon cohort, H. pylori seropositivity was found to be associated with a decreased NSCLC patient survival on anti-PD-1 therapy. The survival median for H. pylori seropositive patients was 6.7 months compared with 15.4 months for seronegative patients (p=0.001). Additionally, in the Montreal cohort, H. pylori seropositivity was found to be associated with an apparent decrease of NSCLC patient progression-free survival on anti-PD-1 therapy. Conclusion: Our study unveils for the first time that the stomach microbiota affects the response to cancer immunotherapies and that H. pylori serology would be a powerful tool to personalize cancer immunotherapy treatment. https://www.pittsburghtribune.org/ https://amazonsale.io/ https://ehealthcareplus.us/ https://www.timessquarereporter.com/ https://edu.pittsburghtribune.org/ https://www.infinityebook.com/ https://www.1stsupplement.com/ https://batik4d.vip/ https://eurl.live/https://eurl.live/us/ https://ingredients.ning.com/ https://jeffbezos.ning.com/
Source: Figshare
Authors: Smith, James, Vaillant, Laurie, Oster, Paul, Riva, Erika, McMillan, Brynn, Begka, Christina, Truntzer, Caroline
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: Helicobacter pylori infection, cancer immunotherapy, immune checkpoint inhibitors, anti-PD-1 therapy, non-small cell lung cancer, gastric microbiota, CD8+ T cell activation, dendritic cells, cancer vaccines, H. pylori seropositivity, treatment response prediction, personalized cancer immunotherapy, colon adenocarcinoma, melanoma, gut microbiota
Open Access status: green
Awards: G505741920, G7116055627
OpenAlex ID: W4310660712
